Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus DIZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus DIZAC.
CENTRAX vs DIZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Dizac is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, resulting in increased chloride ion influx, neuronal hyperpolarization, and inhibition of neuronal excitability.
10-30 mg orally, 3-4 times daily.
10 mg IV/IM every 4-6 hours as needed; max 40 mg/day.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal elimination half-life: 2.5-4 hours in adults; prolonged in renal impairment (up to 20 hours in anuria), neonates, and elderly. Clinical context: Repeated dosing recommended every 4-6 hours.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal (70-80% as unchanged drug and metabolites, primarily via glomerular filtration and active tubular secretion), biliary/fecal (15-20%)
Category C
Category C
Benzodiazepine
Benzodiazepine